Coherus Enjoying Pegfilgrastim Revival As Amgen Royalty Dues Expire

Coherus BioSciences has seen a seismic jump in sales of, and market share for, its US biosimilar pegfilgrastim franchise. The firm is optimistic that the momentum will continue through the year.